TCTR20240626005招募中2 期
A Randomized, Single-center, Subject and Evaluator-blind, Matched-pair, Active-control, Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Revolax Deep with Lidocaine Administrations Compared to Restylane Defyne for Nasolabial Fold Corrections.
ACROSS Co., Ltd. (in HUGEL Inc.)0 个研究点目标入组 100 人开始时间: 2024年6月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Male or female subjects aged 30-65 years.
- •Subjects with WSRS of 3 or 4 for both sides of their face that want to improve the appearance of their nasolabial folds. The scores do not have to be the same on both sides, but the two nasolabial folds should be visually symmetrical within the specified range of 3-4.
- •Subjects who have discontinued the use of any dermatological procedure(s) or therapies (i.e., facial wrinkle reduction) prior to enrollment.
- •Subjects who are capable of comprehending and abiding by protocol instructions.
- •Subjects who are available throughout the trial period.
- •Subjects who are willing to provide written inform consent.
排除标准
- •Subjects who received, or plan to receive coronavirus (MERS-CoV, SARS-CoV, or SARS-CoV-2) vaccination less than 2 weeks from screening.
- •Subjects administered antithrombotic agent(s) less than or equal 2 weeks prior to screening, require antithrombotic agents during the trial period (excluding low dose Aspirin of 100 mg, maximum of 300 mg/day), or nonsteroidal anti-inflammatory drugs (NSAIDs) or Vitamin E less than or equal 1 week prior to screening. Subjects administered Vitamin E should be assessed on a case-by-case basis by the investigator to confirm dosage. Investigators may decide to exclude high-dose Vitamin E subjects to avoid potential antiplatelet effects and bleeding.
- •Subjects with liver problems and/or blood coagulation defects.
- •Subjects with a history of facial topical drug or treatment use less than or equal 4 weeks prior to screening (e.g., steroids, retinoids) or required topical drug or treatment use during the trial period. However, subjects using cosmetic products and devices are not included in this exclusion criteria.
- •Subjects undergoing treatment for wrinkles or acne, facial (chemical) peels, skin rejuvenation procedures, plastic surgeries, and/or botulinum toxin administrations less than or equal 24 weeks prior to screening.
- •Subjects with permanent skin expanders (e.g. soft form or silicone facial implants).
- •Subjects with facial scarring that require medical treatment but have not received any for more than 1 year.
- •Subjects with a history of scars or wounds (e.g., hypertrophic or keloid type scarring) where the investigational device will be administered.
- •Subjects with facial skin diseases or infectious wounds.
- •Subjects with a history of immunodeficiencies or immunocompromise.
- •Subjects with a history of anaphylaxis or severe allergic reactions, or side effects from EMLA cream or other Lidocaine drugs (i.e., during past use of either investigational device).
- •12)Subjects with severe cardiovascular, digestive, pulmonary, endocrine, or central nerve system illness.
- •Subjects with past or present history of mental illness or disorder.
- •Subjects with records of participation in other clinical trials less than 30 days prior to screening. Subjects who have participated in a clinical trial for aesthetic purposes less than 6 months are permitted to enroll at the investigator discretion.
- •Women of child-bearing potential that do not consent to the use of medically approved methods of contraception over the course of the trial. Medically approved methods of contraception include, but are not limited to, condoms, sustained oral contraceptives use more than or equal 3 months, contraceptive shots or suppositories, or IUDs.
- •Women who are pregnant and/or lactating.
- •Subjects with other clinically significant reason(s) as determined by the investigator.
研究者
相似试验
招募中
不适用
A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's FeetKCT0006010S.Biomedics80
已完成
不适用
medical device pivotal clinical study to assess the anti-adhesive effect and safety of ABT13107 compared to Hyalobarrier applied to postoperative intrauterineDiseases of the skin and subcutaneous tissueKCT0002393Medytox192
已完成
不适用
A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.psychiatric disordersSchizofrenia10039628NL-OMON36943Hoffmann-La Roche92
已完成
不适用
A single-center, randomized, investigator/subject-blind, adaptive single-ascending dose (Part 1) and multiple-ascending dose (Part 2), placebo-controlled, parallel study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6889450 following oral administration in healthy subjects.mental disorder characterized by abnormal social behavior and failure to recognize what is real10039628NL-OMON44416F. Hoffmann-La Roche Ltd.164
尚未招募
1 期
A Single-center, Randomnized, Evaluator-blinded, Active-controlled Study to evaluate the effectiveness and Safety of Neuramis deep for Correct in Patients with lip and perioral wrinkles.Male and Female age 20 years or older with perioral wrinkle severity scale (PWSS) of moderate to severePerioral wrinkleTCTR20231008002Medyceles Co., Ltd.60